Washington, DC Law Firm Finkelstein Thompson LLP Investigates Vanda Pharmaceuticals, Inc.

  Washington, DC Law Firm Finkelstein Thompson LLP Investigates Vanda
  Pharmaceuticals, Inc.

Business Wire

WASHINGTON -- June 25, 2013

Shareholder law firm Finkelstein Thompson LLP is investigating potential
claims on behalf of shareholders of Vanda Pharmaceuticals, Inc. (“Vanda” or
“the Company”) (NASDAQ: VNDA). If you are interested in discussing your rights
as a Vanda shareholder, or have information relating to this investigation,
please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050
or by email at contact@finkelsteinthompson.com.

Vanda is currently developing the drug Tasimelteon for treatment of
non-24-hour disorder (“non-24”), a circadian rhythm disorder in which the
patients’ internal “body clock” is misaligned, causing sleep irregularities.

In late May 2013, the Company submitted a new drug approval application for
Tasimelteon to the FDA. However, on June 19, 2013, thestreet.com published an
article alleging several irregularities in the clinical trial process,
including:

  *The design of Vanda's primary Phase III study changed numerous times,
    including a complete replacement of the primary endpoint just one month
    before study results were announced.
  *The replacement primary endpoint installed to assess Tasimelteon's benefit
    was created by Vanda and has never been used before in sleep-drug clinical
    trials, nor was it endorsed by the FDA.
  *Vanda was forced to cut in half the patient enrollment into the
    Tasimelteon clinical trials because totally blind patients with non-24
    could not be identified. Even then, Vanda was only able to enroll patients
    by stretching the clinical definition of non-24.
  *Tasimelteon was only able to demonstrate a benefit for non-24 patients by
    combining data from two phase III studies. Despite Vanda's claims to the
    contrary, the phase III studies may have actually failed on their own.

Following these allegations, Vanda shares declined $2.41 per share, or more
than 22%, to close at $8.51 per share.

Finkelstein Thompson LLP has spent over three decades delivering outstanding
representation to institutional and individual clients in financial
litigation, and courts have appointed it lead or co-counsel in dozens of
shareholder class actions. The firm also serves as local counsel to other
firms pursuing cases in courts throughout the Washington, DC metro area.
Indeed, the firm has served in leadership and liaison roles in cases that have
recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our website at
www.finkelsteinthompson.com. Attorney advertising. Prior results do not
guarantee similar outcomes.

Contact:

Finkelstein Thompson LLP
L. Kendall Satterfield, 877-337-1050